Sign in
Not yet taking people in NetherlandsPhase 2/3

Testing a dye to help surgeons see solid tumor edges

Tests indocyanine green dye imaging to help mark solid tumor edges during surgery in adults.

Key facts

Who runs it
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Where
Rotterdam, NetherlandsSee the site
Registry title
The Surf trial
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
40 people, planned
Started
1 Jan 2026
Expected to end
1 Jan 2029
Type of study
Interventional
Record updated
28 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a solid cancer who will have surgery to remove it. It tests a fluorescent dye called ICG that may show the tumor edges.

Age
18 years or older
Sex
Women and men can both join
Disease stage
Solid cancer confirmed by tissue examination (for example head and neck, gut, liver and bile ducts, breast, urinary and genital organs, sarcoma). Surgery must be planned to remove all of the disease.

Main reasons for not taking part

  • Known allergy to Indocyanine Green (ICG), iodine or shellfish
  • Pregnant or breastfeeding
  • Significant kidney problems (eGFR <50 mL/min/1.73 m²)
  • Overactive thyroid or other active thyroid disease
  • Any condition the investigator thinks puts the person at undue risk or disturbs the study

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥18 years
  • Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)
  • Candidate for surgical resection with curative intent
  • Ability to provide written informed consent
  • Adequate organ function to undergo surgery and ICG administration

Who cannot take part

  • Known allergy to Indocyanine Green (ICG), iodine, or shellfish
  • Hyperthyroidism or other active thyroid disease
  • Any condition deemed by the investigator to place the patient at undue risk or interfere with study procedures
  • Significant renal impairment (eGFR <50 mL/min/1.73 m²)
  • Pregnant or breastfeeding

Where in Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To determine the optimal dose and timing of intravenous ICG to achieve sufficient tumor-to background contrast in solid tumors and to evaluate whether ICG fluorescence imaging can accurately identify tumor margins during surgery.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The SURF trial: Optimizing Surgical excision Using Real-time Fluorescence imaging with indocyanine green
Plain-language title
Testing a dye to help surgeons see solid tumor edgesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 April 2026